Safety of gamma glutamylcysteine supplement in people with mild cognitive impairment
Tests gamma glutamylcysteine supplement doses for safety in people with mild cognitive impairment.
Key facts
- Who runs it
- Pravat Mandal
- Where
- Pittsburgh, United StatesSee the site
- Trial code
- Registry title
- Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 9 people, planned
- Started
- 4 Aug 2026
- Expected to end
- Feb 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- Gamma- Glutamylcysteine
- Gamma- Glutamylcusteine
- Record updated
- 7 August 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with mild cognitive impairment (MCI) and memory complaints. It tests the safety of Gamma Glutamylcysteine (GGC) capsules taken by mouth for 3 months.
- Age
- 55 to 80 years
- Sex
- All sexes
- Disease stage
- A diagnosis of mild cognitive impairment (MCI), with memory complaints. MoCA score (a memory and thinking test) between 18-25.
- Earlier treatment
- People taking antioxidant products (ashwagandha, gingko biloba, N-acetylcysteine or glutathione) cannot join.
Main reasons for not taking part
- History of cancer
- History of schizophrenia or manic-depressive disorder
- Taking antioxidant products (ashwagandha, gingko biloba, N-acetylcysteine or glutathione)
- Abuse of or dependence on illegal drugs (cocaine, heroin, marijuana, or fentanyl)
- Not able to read and write in English
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Memory complaints
- MCI diagnosis
- MoCA score between 18-25
- Age 55 - 80 years old
- Ability to read and write in English
Who cannot take part
- Subjects on antioxidant therapy (ashwagandha, gingko biloba, N-acetylcysteine or glutathione)
- Subjects on illicit drug (cocaine, heroin, marijuana, or fentanyl) abuse/dependence
- Subjects with a history of cancer
- Subjects with a history of schizophrenia, manic-depressive disorder
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 55 and 80 years old?
Where in United States
- UPMC Presbyterian HospitalPittsburgh, United StatesContact: Pravat MandalTaking people
About the trial
What the trial wants to find out
The goal of this study is to evaluate the safety and tolerability of Gamma Glutamylcysteine (GGC) supplement at different doses (400mg/day or 800mg/day or 1200mg/day) when administered orally to patients with MCI over 3 months. This study is designed to generate preliminary clinical safety data to inform the feasibility and design of larger controlled trials.
The 3 groups in the trial
- Gamma - Glutamylcystiene 400Treatment being tested
Each participant will receive gamma-glutamyl cysteine (GGC) capsules orally 400mg once a day for 3 months.
Treatment: Gamma- Glutamylcysteine
- Gamma - Glutamylcystiene 800Treatment being tested
Each participant will receive gamma-glutamyl cysteine (GGC) capsules orally 400mg two times(morning-evening) a day for 3 months
Treatment: Gamma- Glutamylcysteine
- Gamma - Glutamylcystiene 1200Treatment being tested
Each participant will receive gamma-glutamyl cysteine (GGC) capsules orally 400mg three times (morning-afternoon - evening) a day for 3 months
Treatment: Gamma- Glutamylcusteine
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Study For Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients
- Plain-language title
- Safety of gamma glutamylcysteine supplement in people with mild cognitive impairmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Fit questions
- Built from NCT07583251, who can take part
- Record updated
- 7 August 2026